Business Standard

Thursday, December 19, 2024 | 05:36 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Merck's latest trial data show its Covid pill is less effective

Merck's latest trial analysis includes data from all enrolled participants, the drugmaker said in a statement Friday.

Molnupiravir can be given to patients at home, unlike Gilead Sciences Inc.’s antiviral remdesivir and monoclonal antibody therapies, which are administered via an intravenous infusion usually in a hospital or a clinic.
Premium

Representative image

Fiona Rutherford | Bloomberg
Merck & Co. said updated results showed its Covid-19 pill reduced the risk of hospitalization or death among adults with mild to moderate disease by 30%, less than a previous estimate and well below a rival treatment from Pfizer Inc. 
Shares of Merck slid 3.4% to $79.46 in pre-market trading, reversing earlier gains, while Pfizer rose 5.9%. 

Merck’s latest trial analysis includes data from all enrolled participants, the drugmaker said in a statement Friday. Nine deaths were reported in the placebo group, and one in the group receiving the treatment, called molnupiravir. 

The data will be at the center of a Tuesday panel
Topics : Coronavirus

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in